Why am I not losing weight on Mounjaro? A clinical view

First, which question are you asking?

Two situations get described in the same words, and they are not the same thing.

You have never really got going. Weight has barely moved since you started. That is a question about dose, about what else is being treated, and about what has not been looked for.

Mounjaro stopped working. You lost weight steadily and then it stalled, or started coming back. That is a different question with different answers, because the body burns less energy as it gets lighter and a plateau is often the expected end of a phase rather than a failure of treatment.

This article is about the first. If yours is the second, responded and then stalled on Mounjaro is covered separately. For the broader question of limited response to semaglutide and what “GLP-1 resistance” means, see the clinical overview.

Slow is not the same as not working

This is the single most useful thing to know, and it is the part most often missed.

Researchers went back through the SURMOUNT-1 trial and separated out the people who had lost less than 5% of their body weight after twelve weeks on tirzepatide — the group most likely to conclude it was not working and stop. They were not a handful of outliers. They were 278 people out of 1,545, close to one in five.

By week twenty-four, 70% of that group had reached 5% or more. By week seventy-two, 90% had. On average it took them around twenty-five weeks to get there.

So a slow start predicted very little about where people finished. It predicted how long they would take. The ones who gave up at twelve weeks were, in most cases, abandoning treatment roughly three months before it did what they wanted.

One more detail worth knowing, because it tends to reassure the people it describes. Compared with the faster group, the slower responders started out heavier, with a higher BMI and a larger waist, and more of them were men. Slower progress was associated with where they began, not with whether treatment would eventually work.

None of that is an argument for waiting indefinitely. It is an argument for finding out why progress is slow rather than assuming you already know.

Have you reached a treatment dose yet?

Tirzepatide is not started at the dose it is meant to work at. Treatment begins low and increases in steps, so that the body has time to adjust and side effects stay manageable.

The doses studied for weight management in SURMOUNT-1 were 5 mg, 10 mg and 15 mg. The starting dose is lower than all of them.

So someone three months in, who has had a slow titration because of nausea or because a review was delayed, may simply not have arrived yet. "It is not working" and "I have not yet reached a dose that does much" look identical from the outside and are entirely different problems.

This is the first thing worth establishing, and it is often the whole answer.

What else are you taking?

A considerable number of commonly prescribed medicines cause weight gain or make weight loss harder. They are prescribed for good reasons, and nobody should stop one because of this article. But if something is actively working against the treatment, that changes what a reasonable expectation looks like.

The classes most often involved include some antidepressants and antipsychotics, corticosteroids, certain diabetes treatments including insulin and some older tablets, several drugs used for epilepsy and migraine, and some blood pressure medicines.

Often there is an alternative within the same class with a different weight profile. Sometimes there is not, and the honest conversation is about what is realistic while that medicine is necessary. Either way it has to be known about.

What has not been looked for

Weight that does not respond is sometimes weight that is being driven by something nobody has assessed.

An underactive thyroid that is undertreated. Polycystic ovary syndrome and the insulin resistance that often comes with it. Cortisol excess. A pituitary cause. Obstructive sleep apnoea, which disrupts the hormones controlling appetite and makes everything harder. Perimenopause, where the metabolic shift is real and frequently dismissed.

None of these mean treatment will not work. Several of them mean it will work considerably better once they are also being treated. That is the point of a specialist assessment rather than a repeat prescription.

What muscle has to do with it

Weight loss of any kind takes some muscle with it, and muscle is where a large part of resting energy expenditure lives. Lose enough of it and the body burns less at rest than it did, which makes further loss harder and regain easier.

This is why protein intake and resistance exercise are not optional extras alongside treatment, and why body composition — what the weight is made of — tells you more than the number alone.

What an assessment actually involves

Not a repeat prescription and not a review of the scales.

A full history, including everything else being treated and every medicine being taken. Blood tests covering thyroid function, glucose and insulin resistance, liver, kidney and the relevant hormones. Body composition rather than weight alone. A proper look at sleep, mood and appetite, because all three affect what is possible.

Then a plan that accounts for what is found, including the parts that are not about the medicine at all.

When to ask for a review

If you have been on treatment for three months and nothing has changed, that is worth investigating rather than enduring — not because the treatment has failed, but because something identifiable is usually in the way.

If you are being managed by a service that only adjusts the prescription, the assessment described above is unlikely to have happened.